Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/25/26
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026GlobeNewsWire • 03/18/26
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 MillionGlobeNewsWire • 02/23/26
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 MillionGlobeNewsWire • 02/23/26
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe DiseaseGlobeNewsWire • 02/23/26
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United StatesGlobeNewsWire • 01/13/26
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA ResubmissionGlobeNewsWire • 12/15/25
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in DermatologyGlobeNewsWire • 12/10/25
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/14/25
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/12/25
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome TherapeuticsGlobeNewsWire • 11/06/25
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025GlobeNewsWire • 11/05/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIOPRNewsWire • 10/28/25
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology ConferenceGlobeNewsWire • 10/24/25
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of GoutGlobeNewsWire • 10/21/25
Journey Medical Corporation to Participate in October 2025 Investor ConferencesGlobeNewsWire • 10/08/25
INVESTOR ALERT: Investigation of Fortress Biotech, Inc. (FBIO) Announced by Holzer & Holzer, LLCGlobeNewsWire • 10/01/25
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A FinancingGlobeNewsWire • 10/01/25
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101GlobeNewsWire • 10/01/25
Journey Medical Corporation to Participate in September 2025 Investor ConferencesGlobeNewsWire • 09/03/25
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/02/25